Navigation Links
FDA Approves Five-Day Dosing Regimen for Dacogen(R) (decitabine) for Injection, Offering a New Outpatient Dosing Option for Myelodysplastic Syndromes (MDS)
Date:3/11/2010

y began marketing its first product in the United States in 1997 and has rapidly grown to become a fully integrated pharmaceutical business with fiscal year 2008 (year ended March 31, 2009) sales of approximately $3.7 billion.  Eisai Inc.'s areas of commercial focus include neurology, gastrointestinal disorders and oncology/critical care.  The company serves as the U.S. pharmaceutical operation of Eisai Co., Ltd., a research-based human health care (hhc) company that discovers, develops and markets products throughout the world.  

Eisai has a global product creation organization that includes U.S.-based R&D facilities in Maryland, Massachusetts, New Jersey, North Carolina and Pennsylvania as well as manufacturing facilities in Maryland and North Carolina.  The company's areas of R&D focus include neuroscience; oncology; vascular, inflammatory and immunological reaction; and antibody-based programs.  For more information about Eisai, please visit www.eisai.com.

ADDITIONAL SUGGEST
'/>"/>

SOURCE Eisai Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. European Union Approves Corn Stack with Herculex RW and Roundup Ready 2 Traits for Food, Feed, Import and Processing
2. EU Committee Approves New Food Applications for Marteks lifesDHA(TM)
3. EU Committee Approves New Food Applications for Martek's life'sDHA™
4. Photos: FDA Approves 12-Month Labeling Update for EVOLENCE(R) Collagen-Based Facial Filler
5. FDA Approves Labeling Change for VYVANSE(R) (lisdexamfetamine dimesylate) CII to Include Supplementary Clinical Data Supporting Efficacy at 13 Hours Postdose in Children Aged 6 to 12 with ADHD
6. FDA Approves Boston Scientifics Next-Generation TAXUS(R) Liberte(R) Atom(TM) Stent System
7. Arpida Annual General Meeting of Shareholders Approves All Board Proposals
8. Health Canada Approves SIMPONI(TM) (golimumab) for Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
9. FDA Approves Label Change for Non-Invasive Fibroid Treatment
10. FDA Approves SyntheMeds REPEL-CV(R) Adhesion Barrier for Use in Pediatric Cardiac Surgery
11. FDA Approves SYMBICORT(R) for Chronic Obstructive Pulmonary Disease (COPD)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2015)... 2015 Ryan & Maniskas, LLP that ... District Court for the Northern District of California ... purchased the common stock of Avalanche Biotechnologies, Inc. ("Avalanche" or ... and June 15, 2015, inclusive (the "Class Period"). ... the Court for appointment as a lead plaintiff of the ...
(Date:7/24/2015)... Agritech Limited (NASDAQ GS: SEED) ("Origin", or the "Company"), a ... , today announced that the Company will report results for ... before the market opens on Wednesday, August 5th, 2015. ... 2015, at 9:00 a.m. ET / 9:00 p.m. ... in the call, please dial the following numbers approximately 5 ...
(Date:7/23/2015)... ... July 23, 2015 , ... The health and wellness of brain ... management of a brain tumor diagnosis. The American Brain Tumor Association presents interactive sessions ... Patient and Family Conference, July 24-25 in Chicago. , “We have understood for ...
(Date:7/23/2015)... ... 2015 , ... The Pittcon 2016 Program Committee is extremely pleased to announce ... Professor, by courtesy, of Applied Physics at Stanford University, will present the Wallace ... Nanoscopy in Cells and Beyond” , Dr. Moerner’s lecture will focus on his ...
Breaking Biology Technology:Ryan & Maniskas, LLP Announces Class Action Lawsuit Against Avalanche Biotechnologies, Inc. 2Ryan & Maniskas, LLP Announces Class Action Lawsuit Against Avalanche Biotechnologies, Inc. 3Origin Agritech Limited to Announce Third Quarter Fiscal 2015 Unaudited Financial Results on August 5th, 2015 2Origin Agritech Limited to Announce Third Quarter Fiscal 2015 Unaudited Financial Results on August 5th, 2015 3Reframing the Caregiver and Patient Mindset: Coping with the ‘New Normal’ 2Reframing the Caregiver and Patient Mindset: Coping with the ‘New Normal’ 3The 2014 Nobel Prize in Chemistry Recipient W. E. Moerner, to Deliver Wallace H. Coulter Lecture at Pittcon 2016 2The 2014 Nobel Prize in Chemistry Recipient W. E. Moerner, to Deliver Wallace H. Coulter Lecture at Pittcon 2016 3
... Appear in Sept. 9 Issue of the Journal Nature ... hits with,devastating effects in people with normal cholesterol levels, ... risk factors. A new,research discovery may help explain why ... Researchers at Cleveland Clinic,s Lerner Research Institute have,discovered ...
... CLAREMONT, Calif., Sept. 10 /Xinhua-PRNewswire-FirstCall/,-- Kiwa Bio-Tech Products ... China Green Food Association of the Agriculture Ministry,("CGFA") ... Food CGFA,Recommend Brands." The vice president of ... over 13 million hm2 (hectares) of planting area ...
... UBC ClinResearch to Expand Global Reach in Pioneering ... BioSource Corporation,(UBC) today announced the acquisition of an ... technology solutions and services for,flexible, or adaptive, clinical ... employees, ClinResearch has designed and implemented 80,adaptive programs ...
Cached Biology Technology:Cleveland Clinic-Led Research Uncovers New Mechanism That Heightens Risk of Heart Disease 2Cleveland Clinic-Led Research Uncovers New Mechanism That Heightens Risk of Heart Disease 3Kiwa Bio-Tech Named Recommended Brand by the China Green Food Association 2United BioSource Acquires Interest in Leading Adaptive Design Technology Service Provider 2
(Date:6/24/2015)... This report provides market analysis of the ... It contains an analysis of the drivers, challenges, and ... from the short, medium, and long term perspective landscapes. ... and technology trends that currently, prevail in the market. ... to efficiently manage the increasing marine traffic and increasing ...
(Date:6/24/2015)... , June 22, 2015 ... the addition of the "Huawei Ascend Mate ... report to their offering. Huawei,s technological ... the opposite direction than Apple,s and Samsung,s one. ... sensor developed by Fingerprint Cards, a main actor ...
(Date:6/23/2015)... , June 23, 2015   MedNet Solutions ... supports the entire spectrum of clinical research, is ... ™ , the company,s intuitive, flexible and ... a Silver 2015 Stevie® Award by the ... & Services Website category.  The American Business Awards ...
Breaking Biology News(10 mins):Automatic Identification System Market by Class, by Platform, by Application and by Geography - Global Forecasts & Analysis to 2014 - 2020 2Huawei Ascend Mate 7 Fingerprint Sensor - Reverse Costing Analysis 2MedNet Solutions' iMedNet eClinical Wins Silver Stevie Award 2
... scientists survey five New York flu seasons , On the ... for Genomic Research (TIGR) have captured influenza evolution in action. ... , the researchers report the first large-scale project to sequence ... the rapidly evolving flu virus in a human population--and a ...
... Using functional magnetic resonance imaging, or fMRI, researchers at the ... the act of recalling a memory is a bit like ... 23 edition of the journal Science, demonstrates that the same ... are activated when a person attempts to recall that event ...
... medical research team has identified a new gene linked ... a previously discovered gene known to increase the risk ... Edinburgh and Glasgow, together with scientists from the pharmaceutical ... of the second gene, phosphodiesterase 4B (PDE4B) in the ...
Cached Biology News:First big influenza genome study reveals flu evolution 2First big influenza genome study reveals flu evolution 3First big influenza genome study reveals flu evolution 4Researchers know what you were about to say; fMRI used to detect memory storage and retrieval 2Scientists move forward understanding of schizophrenia 2
For the differentiation of mouse embryonic stem cells tooligodendrocytes....
Preadipocyte factor-1 [Pref-1, DLK-1], C-terminal...
IC50: 35 ng/ml · Limit of detection: 8 ng/ml...
, Glycerol 30%...
Biology Products: